NIKKEI 225
38,299.71 +25.66 (+0.07%) HANG SENG
18,110.35 +347.32 (+1.96%) CRUDE OIL
79.44 +0.44 (+0.56%) GOLD FUTURES
2,328.40 +17.40 (+0.75%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,790.43 -2,159.07 (-4.50%)
Jazz Pharmaceuticals PLC (J7Z.SG)
| Previous close | 103.10 |
| Open | 102.45 |
| Bid | 102.95 x 50000 |
| Ask | 103.70 x 50000 |
| Day's range | 102.45 - 103.60 |
| 52-week range | 99.32 - 133.00 |
| Volume | |
| Avg. volume | 6 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care Conference on Wednesday, May 15, 2024, in Las Vegas. The fireside chat will be held at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.
- PR Newswire
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2024 and affirmed guidance for 2024.
- PR Newswire
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago. Presentations include data from trials of zanidatamab, Zepzelca® (lurbinectedin), and Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn). A poster featuring the study design for the JZP898 Phase 1 trial in progress will also be presented.
